| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 17, 2023 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 16,000 | $217.74 | $3,483,775.56 | -23.5% | +4.5% | +7.3% | |
| Mar 16, 2023 | AMLX Amylyx Pharmaceuticals, Inc. | Klee Justin B.60 | Co-chief Executive Officer | Sell | 100,000 | $31.86 | $3,186,236.20 | -1.8% | -22.4% | -89.9% | |
| Mar 16, 2023 | AMLX Amylyx Pharmaceuticals, Inc. | Frates James M83 | Chief Financial Officer | Sell | 32,500 | $31.89 | $1,036,459.19 | -87.3% | -22.4% | -89.9% | |
| Mar 16, 2023 | UTHR United Therapeutics Corp | Mahon Paul A47 | EVP &General Counsel | Sell | 6,000 | $214.39 | $1,286,342.45 | -3.0% | +2.8% | +7.1% | |
| Mar 16, 2023 | AMLX Amylyx Pharmaceuticals, Inc. | Milne George M Jr59 | Director | Sell | 35,000 | $31.89 | $1,116,072.45 | -2.0% | -22.4% | -89.9% | |
| Mar 16, 2023 | AMLX Amylyx Pharmaceuticals, Inc. | Morningside Venture Investments Ltd93 | 10% Owner | Sell | 9,122 | $32.55 | $296,921.10 | -0.1% | -22.4% | -89.9% | |
| Mar 16, 2023 | AMLX Amylyx Pharmaceuticals, Inc. | Firestone Karen | Director | Buy | 1,000 | $31.99 | $31,990.00 | New | -22.4% | -89.9% | |
| Mar 16, 2023 | AMLX Amylyx Pharmaceuticals, Inc. | Yeramian Patrick D84 | Chief Medical Officer | Sell | 54,627 | $31.87 | $1,741,200.40 | -15.3% | -22.4% | -89.9% | |
| Mar 16, 2023 | AMLX Amylyx Pharmaceuticals, Inc. | Cohen Joshua B60 | Co-chief Executive Officer | Sell | 100,000 | $31.86 | $3,186,335.98 | -1.8% | -22.4% | -89.9% | |
| Mar 15, 2023 | LNTH Lantheus Holdings, Inc. | Sabens Andrea47 | Chief Accounting Officer | Sell | 386 | $71.58 | $27,629.88 | -0.6% | +17.3% | -18.3% | |
| Mar 15, 2023 | AMPH Amphastar Pharmaceuticals, Inc. | Peters William J52 | CFO, EVP &Treasurer | Sell | 12,776 | $36.43 | $465,471.84 | -9.7% | +27.9% | +17.2% | |
| Mar 15, 2023 | COLL Collegium Pharmaceutical, Inc | Tupper Colleen45 | EVP &Chief Financial Officer | Sell | 31,640 | $23.77 | $752,165.06 | -23.1% | -4.1% | +60.8% | |
| Mar 15, 2023 | LNTH Lantheus Holdings, Inc. | Marshall Robert J. Jr.53 | CFO And Treasurer | Sell | 5,000 | $71.58 | $357,900.00 | -3.8% | +17.3% | -18.3% | |
| Mar 15, 2023 | TCNNF Trulieve Cannabis Corp. | Rivers Kim A. | Chairman And CEO | Buy | 4,110 | $6.08 | $24,984.28 | +0.2% | - | - | |
| Mar 15, 2023 | BTAI Bioxcel Therapeutics, Inc. | O'Neill Vincent86 | Chief Medical Officer | Sell | 845 | $19.70 | $16,642.28 | -40.5% | +2.8% | -85.4% | |
| Mar 15, 2023 | AMLX Amylyx Pharmaceuticals, Inc. | Morningside Venture Investments Ltd93 | 10% Owner | Sell | 220,714 | $33.68 | $7,433,458.52 | -1.0% | -24.8% | -90.6% | |
| Mar 15, 2023 | BTAI Bioxcel Therapeutics, Inc. | Steinhart Richard I87 | Chief Financial Officer | Sell | 2,084 | $19.50 | $40,638.00 | -58.1% | +2.8% | -85.4% | |
| Mar 15, 2023 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 16,000 | $219.86 | $3,517,722.25 | -35.1% | +5.5% | +9.5% | |
| Mar 15, 2023 | BTAI Bioxcel Therapeutics, Inc. | Rodriguez Javier87 | See Remarks | Sell | 950 | $19.63 | $18,643.75 | -45.6% | +2.8% | -85.4% | |
| Mar 15, 2023 | BTAI Bioxcel Therapeutics, Inc. | Yocca Frank88 | Chief Scientific Officer | Sell | 985 | $19.69 | $19,395.73 | -9.4% | +2.8% | -85.4% | |
| Mar 15, 2023 | PFE Pfizer Inc | Damico Jennifer B.58 | SVP &Controller | Sell | 9,912 | $40.02 | $396,678.24 | -52.4% | 0.0% | -30.2% | |
| Mar 14, 2023 | EOLS Evolus, Inc. | Avelar Rui67 | See Remarks | Sell | 14,906 | $8.47 | $126,237.42 | -4.2% | -5.5% | +61.2% | |
| Mar 14, 2023 | EOLS Evolus, Inc. | Moatazedi David68 | See Remarks | Sell | 64,211 | $8.47 | $543,796.54 | -9.4% | -5.5% | +61.2% | |
| Mar 14, 2023 | HIMS Hims & Hers Health, Inc. | Boughton Soleil | Chief Legal Officer | Sell | 2,000 | $9.09 | $18,180.00 | -1.2% | +3.6% | +74.2% | |
| Mar 14, 2023 | SUPN Supernus Pharmaceuticals, Inc. | Mottola Frank | Sr VP, Quality, Gmp Oper. &It | Sell | 4,780 | $35.99 | $172,022.64 | -50.2% | -6.5% | -4.7% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.